

Global Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market To Expand At 10.7% CAGR During The Forecast Period


*The Business Research Company's
Ribonucleic Acid (RNA) In Situ
Hybridization (ISH) Global Market Report
2026 – Market Size, Trends, And Forecast
2026-2035*

LONDON, GREATER LONDON, UNITED KINGDOM, September 22, 2026 /EINPresswire.com/ -- A closer look at the ribonucleic acid (RNA) in situ hybridization (ISH) market reveals a rapidly expanding field driven by advances in molecular diagnostics and growing research interests. This technique, essential for identifying RNA sequences within cells, is gaining traction due to its precision and applications in disease diagnosis and personalized medicine. Here's an overview of the market size, key growth factors, regional dynamics, and technological trends shaping its future.

Market Size and Growth Outlook for RNA in Situ Hybridization ISH

The RNA in situ hybridization (ISH) market has shown remarkable growth, with its size projected to increase from \$1.49 billion in 2025 to \$1.66 billion in 2026, representing an 11.1% compound annual growth rate (CAGR). This expansion during the past years has been driven by growing research into cancer biomarkers, increased funding for molecular biology in academia, wider use of fluorescence microscopy, rising infectious disease diagnostics, and improvements in early nucleic acid detection methods.

Looking ahead, the market is expected to accelerate even further, reaching \$2.49 billion by 2030



at a CAGR of 10.7%. The anticipated growth stems from the rising demand for precision oncology, adoption of spatial transcriptomics technologies, expanding personalized medicine applications, automation in laboratory workflows, and increased investments in genomic research infrastructure. Cutting-edge developments like AI-assisted spatial transcriptomics, ultra-sensitive multiplex probes, automated slide hybridization platforms, advanced fluorescent imaging systems, and innovations in single-cell expression profiling are also fueling growth by enhancing RNA signal detection and analysis.

Download a free sample of the ribonucleic acid (rna) in situ hybridization (ish) market report: https://www.thebusinessresearchcompany.com/sample_request?id=67867496&type=smp&name=Ribonucleic%20Acid%20%28RNA%29%20In%20Situ%20Hybridization%20%28ISH%29%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=paid&utm_campaign=Sep_PR

Understanding RNA in Situ Hybridization ISH Technique

RNA in situ hybridization (ISH) is a molecular technique that allows scientists and clinicians to detect and visualize specific RNA sequences directly within cells or tissue samples while maintaining the sample's structural integrity. This method uses labeled complementary probes that bind to target RNA molecules, enabling microscopic examination of gene expression patterns and localization within the cellular context, which is critical for both research and diagnostic purposes.

Factors Boosting Growth in the [RNA in Situ Hybridization ISH Market](#)

One important driver of the RNA in situ hybridization (ISH) market is the increasing focus on infectious disease detection. This involves the growing use of advanced molecular diagnostic techniques to identify viral, bacterial, and other pathogen infections through detailed laboratory analysis. RNA ISH aids in this area by pinpointing pathogen-specific RNA in tissue samples, allowing precise visualization of infected cells without disturbing tissue morphology. For instance, in May 2026, the UK Health Security Agency reported 630 confirmed measles cases in England from January to May, showing an increase from prior months. Such trends in infectious disease surveillance emphasize the need for effective RNA detection methods, boosting market growth.

View the full ribonucleic acid (rna) in situ hybridization (ish) market report:

https://www.thebusinessresearchcompany.com/report/ribonucleic-acid-rna-in-situ-hybridization-ish-market-report?utm_source=EINPresswire&utm_medium=paid&utm_campaign=Sep_PR

Expanding Role of Precision Medicine in Market Growth

Another significant factor is the rising adoption of precision medicine, which tailors prevention, diagnosis, and treatment to an individual's genetic and molecular profile. This personalized healthcare approach is gaining momentum due to the growing burden of chronic diseases, especially cancer, where targeted therapies are crucial. RNA in situ hybridization supports precision medicine by identifying RNA biomarkers within tissues, enabling detailed molecular profiling that guides customized treatment decisions. For example, in February 2024, the

Personalized Medicine Coalition highlighted that the FDA approved 16 new personalized treatments for rare diseases in 2023, more than double the six approvals in 2022. Such advancements underscore the expanding role of RNA ISH in precision diagnostics and therapeutics.

Regional Outlook: Leadership and Fastest Growing Markets in RNA in Situ Hybridization ISH
In 2025, North America led the RNA in situ hybridization (ISH) market in terms of size, benefiting from strong healthcare infrastructure, research funding, and technological adoption. However, the Asia-Pacific region is expected to experience the fastest growth during the forecast period due to increasing healthcare investments, rising prevalence of infectious and chronic diseases, and expanding research activities. Besides North America and Asia-Pacific, the market report also covers other important regions including South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive view of global market trends and opportunities.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: marketing@tbrc.info

[The Business Research Company](https://www.thebusinessresearchcompany.com) - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/944195940>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.